Cytokinetics, Incorporated announced that two posters relating to CK-2017357 are scheduled to be presented at the 22nd Annual Sessions of the Society for Vascular Medicine to be held June 2-4, 2011 at the Seaport Hotel in Boston, MA. One poster will highlight the results from a Phase IIa Evidence-of-Effect clinical trial evaluating CK-2017357 in patients with claudication associated with peripheral artery disease and the other poster will provide support for the validation of a novel functional endpoint, bilateral heel raise test, in this patient population.
CK-2017357, the lead drug candidate from the company’s skeletal muscle contractility program, is a fast skeletal muscle troponin activator and is in Phase IIa clinical trials. CK-2017357 selectively activates the fast skeletal muscle troponin complex by increasing its sensitivity to calcium, leading to an increase in skeletal muscle force. This mechanism of action has demonstrated pharmacological activity in preclinical models that may relate to the potential treatment of diseases associated with aging, muscle wasting or neuromuscular dysfunction.